StockData
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Personalis, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$15.88+0.23 (+1.47%)

Close on Oct 19, 2026

Market cap
$1.67B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 4, 2026After market close$22.40M$-0.30–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026After market close$15.50M$-0.29–
Q4 FY2025
Ended Dec 31, 2025
Jan 8, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025After market close$14.50M$-0.24–
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025After market close$17.20M$-0.23–
Q1 FY2025
Ended Mar 31, 2025
May 6, 2025After market close$20.60M$-0.18–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025After market close$16.80M$-0.23–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024After market close$25.70M––
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024After market close–––

Company guidance

Outlook given with results on May 7, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Gross marginfull year of 202615% to 20%New
Clinical test volumefull year of 202643,000 to 45,000New
Net lossfull year of 2026-$105.00MNew
Cash usagefull year of 2026$100.00MRaised
Revenue from population sequencing and enterprise salesfull year of 2026$13.00MLowered
Total company revenuefull year of 2026$78.00M to $80.00MNew
Clinical revenuefull year of 2026$10.00M to $11.00MLowered
Revenue from pharma testing services and all other customersfull year of 2026$55.00M to $56.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Personalis filed with the SEC